Fujimasa Tada, Atsushi Hiraoka, Kosuke Nakatani, Kana Matsuoka, Mai Fukumoto, Takuya Matsuda, Emi Yanagihara, Hironobu Saneto, Taisei Murakami, Kei Onishi, Hirofumi Izumoto, Shogo Kitahata, Kozue Kanemitsu-Okada, Tomoe Kawamura, Taira Kuroda, Jun Hanaoka, Jota Watanabe, Hiromi Ohtani, Osamu Yoshida, Masashi Hirooka, Hideki Miyata, Eiji Tsubouchi, Masanori Abe, Bunzo Matsuura, Tomoyuki Ninomiya, Yoichi Hiasa
BACKGROUND/AIM: Unresectable recurrence after curative treatments for hepatocellular carcinoma (HCC) is a life-limited event. Although the IMbrave050 trial (IM050) showed a favorable reduction in recurrence with adjuvant immune-combination chemotherapy, inclusion criteria of the radiofrequency ablation (RFA) group were lower risk than that of the resection group. This study aimed to elucidate the clinical features of patients treated with RFA, which really need adjuvant-chemotherapy. METHODS: From 2000 to 2022, 528 patients with Child-Pugh A and HCC within the Milan criteria (MC), who met the IM050 criteria for RFA and undergone resection or RFA, were enrolled (71 years, HCV:HBV:HBV/HCV:alcohol:others = 337:44:5:53:89, multi-tumor = 138, RFA:resection = 309:219)...
March 26, 2024: Clinical Journal of Gastroenterology